Efficacy of Extended Letermovir Prophylaxis to Prevent CMV Reactivation in High-Risk Chinese Adults Undergoing Allogeneic HSCT

NCT06812598 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

330

Enrollment

OTHER

Sponsor class

Conditions

Cytomegalovirus Infections
CMV

Interventions

DRUG: Letermovir (0-24w）
DRUG: Letermovir (0-14w）

Sponsor

The First Affiliated Hospital of Soochow University